Xlue launches with $35M seed led by Conviction for disease risk models
Xlue, a Pittsburgh company spun out of Carnegie Mellon, builds models that predict cancer and disease risk from patient health records. Conviction led the $35M seed round. The company had earlier raised $1.5M in a friends and family round, and its chief executive spent five years building language models at Microsoft Research.
The round puts a large seed check behind clinical prediction, a category where buyers are hospitals and payers, so data access and validation tend to set the pace more than model release cycles. No valuation has been reported in the coverage reviewed.
For founders, the lesson is that a research-led team with a clear data thesis can raise at seed scale. In health AI, teams should line up data partnerships and validation plans before they expand the product roadmap.